Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New cancer drug shows promise in early trial

NCT ID NCT05577182

First seen Nov 03, 2025 · Last updated May 25, 2026 · Updated 23 times

Summary

This early-phase study tested a new drug called INCA32459 in 46 people with advanced cancers that had spread or couldn't be removed. The main goal was to check the drug's safety and find the best dose. Researchers also looked for signs that the drug might shrink tumors. The study is now complete.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCIES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Centro Integral Oncologico Clara Campal

    Madrid, 28050, Spain

  • Centro Ricerche Cliniche Di Verona (Crc)

    Verona, 37134, Italy

  • Chu Ucl Namur University Hospital Mont-Godinne

    Yvoir, 05530, Belgium

  • Cliniques Universitaires Ucl Saint-Luc

    Brussels, 01200, Belgium

  • Hospital Quironsalud Barcelona

    Barcelona, 08023, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario Quironsalud Madrid

    Pozuelo de Alarcón, 28223, Spain

  • Ico Institut Catala D Oncologia

    L'Hospitalet de Llobregat, 08906, Spain

  • The Angeles Clinic and Research Institute

    Los Angeles, California, 90025, United States

  • Universitair Ziekenhuis Antwerpen (Uza)

    Edegem, 02650, Belgium

  • Universitair Ziekenhuis Brussel

    Jette, 01090, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, 09000, Belgium

  • University of Texas Md Anderson Cancer Center

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.